Spain caps medicine copays at €8–€61

Medicines are one of those costs that look small until they are not. A few euros here, a refill there, and then someone with several chronic prescriptions is suddenly paying enough each month to start skipping doses. That is the problem Spain’s government moved on Tuesday, May 12, 2026. The cabinet approved a decree that changes how prescription copays work, tying them more tightly to income and, for the first time, putting monthly ceilings on what many lower- and middle-income patients can pay. ### What was broken in the old system? Spain already had a public drug benefit, but the copay structure was blunt. Working-age patients were grouped into broad bands, and many people with modest incomes still had no real monthly protection if they needed several medicines for a long time. The result was predictable — the people most likely to be “polymedicated,” meaning they take multiple drugs, could end up carrying a heavy recurring bill even when they were nowhere near wealthy. (sanidad.gob.es) ### What changes now? The decree expands the income brackets for active workers and their beneficiaries from three to six bands. More important than the extra bands, though, is the cap system. People earning under €9,000 a year will face a monthly ceiling of €8.23. Those on €9,000 to €17,999 will be capped at €18.52. Those on €18,000 to €34,999 will be capped at €61.75. The government says these groups previously had no specific monthly limits at all. (sanidad.gob.es) ### Why do caps matter more than percentages? Because a percentage sounds fair until someone needs a lot of medicine. A 40% copay on one prescription may be manageable. A 40% copay across five or six recurring prescriptions is a different story. The cap works like a circuit breaker — once monthly spending hits the ceiling, the bill stops climbing. That matters most for chronic patients, older working-age adults, and anyone whose treatment is long, complex, or both. (sanidad.gob.es) This is an inference from how the ceiling structure works, but it matches the government’s focus on adherence and prolonged treatment. ### Does anyone pay more? The government is framing the reform as progressive rather than across-the-board more expensive. Its line is that the new structure adapts contributions to “real economic capacity” without increasing what existing groups were already paying as a general rule, while making the schedule more graduated at higher incomes. The political point here is clear — protect lower and middle incomes without blowing up the whole financing model. (sanidad.gob.es) ### Why is the government doing this now? Partly because cost-of-living pressure makes every recurring household expense more painful. But the sharper reason is treatment abandonment. Health officials said some patients were interrupting or reducing treatment for economic reasons. That is bad for patients first, but it is also bad for the health system — skipped medicines can turn into worse illness and more expensive care later. (sanidad.gob.es) ### What else moved with it? The same cabinet meeting also advanced a separate bill on public-private collaboration in healthcare. The idea is to make outsourcing more exceptional and more tightly controlled. That is a different policy lever, but it fits the same message — the government is trying to present access, continuity of care, and equity as one connected problem rather than three separate ones. (sanidad.gob.es) ### What is the real bottom line? Basically, Spain is saying prescription copays should still exist, but they should stop snowballing for people who need medicines the most. The headline numbers — €8.23, €18.52, and €61.75 a month for incomes below €35,000 — are the practical part. The bigger shift is philosophical: drug coverage is being treated less like a flat fee schedule and more like a pressure point that can push people out of treatment if the state gets the design wrong. (20minutos.es) (sanidad.gob.es)